Search PubMed⌕ Search

Biomedical subjects

F Cavalli

Publications and source records attributed to F Cavalli.

At least 307 records · Page 17Linked to original sources
PubMed1978

[Bladder carcinoma associated with long-term treatment with cyclophosphamide for multiple myeloma (author's transl)].

A report is presented of a female patient who developed an extensive bladder carcinoma with severe hemorrhaging after many years of treatment with cyclophosphamide for multiple myeloma. The severe hemorrhage could only be controlled by drainage of the urine. The possible causes of the development of a second neoplasia, particularly of urinary bladder carcinoma following long-term therapy with cyclophosphamide, are discussed.

Aged↗
PubMed1977

[Therapeutic results using VP 16-213 alone or in combination with 5-fluorouracil in liver cancer (hepatoma)].

The podophyllotoxin derivative VP 16-213 was used as monotherapy in 6 patients and combined with 5-fluorouracil in another 6. Of the 12 patients treated, 11 had measurable tumor criteria and 5 of these responded to treatment. These responses were attributed mainly to the effects of VP 16-213. Patients responding to chemotherapy lived significantly longer than non-responders. Each case of objective tumor response was accompanied by subjective improvement. In view of these results, a more active approach to the treatment of hepatocellular carcinoma would seem to be justified.

Adult↗
PubMed1977

[Prolymphocytic leukaemia: a new clinical entity (author's transl)].

A 67-year-old woman, at first diagnosed to have acute lymphocytic leukaemia, developed all the characteristic signs of so-called prolymphocytic leukaemia, namely severe general symptoms of illness, marked hepatosplenomegaly in the absence of lymphadenopathy, extreme leukocytosis (at times more than 1000 x 10(9)/l). Prolymphocytic leukaemia is now considered to be an especially unfavourable form of chronic lymphocytic leukaemia.

Aged↗
PubMed1977

[Therapeutic results and prognostic factors in acute lymphatic leukemia in the adult].

Induction chemotherapy consisting of vincristine, prednisone and L-asparaginase was given to 22 adult patients with acute lymphatic leukemia. Manintenance treatment consisted of methotrexate, 6-mercaptopurine, prednisone and vincristine. Of the 22 patients treated, 14 had a complete remission. The median remission duration was 14 months and the median survival 20 months. 8 further patients were included in an attempt to determine the significance of prognostic factors, but none of the parameters studied influence the course of disease with statistical significance. In general, younger patients and those with lower leukocyte counts at the time of diagnosis seemed to fare better.

Adult↗
PubMed1977

[Combination chemotherapy in acute blast crisis of chronic myeloid leukaemia (author's transl)].

Sixteen patients in an acute blast crisis of chronic myeloid leukaemia (CML) were treated with a combination of vincristine, 6-mercaptopurine, hydroxyurea and prednisone. Only two of these patients had complete remission on this treatment, while four had partial remission. This experience, comparable to that reported by others, suggests that aggressive treatment in the terminal phase of CML is justified only as part of a prospective and well-controlled study.

Adolescent↗
PubMed1977

[Acute myeloid leukaemia in the course of Hodgkin's disease (author's transl)].

Acute myeloid leukaemia occurred in six patients who had been treated for Hodgkin's disease for a number of years. Usually the leukaemia diagnosis was preceded by a striking pancytopenic phase, bone-marrow aspiration being more useful diagnostically than biopsy. Five of these six patients have come under observation in the last eighteen months. This extraordinary frequency of secondary acute myeloid leukaemia once again raises the question of the leukaemogenic effect of intensive radiotherapy and chemotherapy, and also new aspects in the therapeutic management of Hodgkin's disease, especially combined radiotherapy and chemotherapy, as well as long-term maintenance chemotherapy.

Adolescent↗
PubMed1977

[VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].

Thirty patients with bronchogenic carcinoma underwent an 8 week course of induction therapy consisting of cyclophosphamide, methotrexate, vincristine, and VP 16-213 (NSC 141 540). Those who achieved objective remission or tumor stabilization were then placed on an intermittent treatment schedule with the same drugs. Of the 30 patients, 17 had an objective response, 5 were unchanged and 8 progressed. Responses were more frequent in anaplastic carcinoma (13/19) than epidermoid or adenocarcinoma (4/11). The toxicity mainly consisted of leukopenia, thrombopenia, alopecia, nausea and vomiting. The implications of these findings in the planning of further chemotherapeutic programs are discussed.

Adenocarcinoma↗
PubMed1976

[The treatment of acute myelocytic leukemia during the first recurrence by means of a new cytostatic combination].

Fifteen patients with acute myeloic leukemia in the first relapse following initial therapy were treated with a combination of adriamycin, vincristine, 6-thioguanine and the new podophyllotoxin derivative VP 16-213. Complete remission was obtained in 3 cases and partial remission in 3 further patients. The combination was generally well tolerated. These preliminary results are compared with those available in the relatively meagre literature. The study is being continued.

Cytarabine↗
PubMed1976

[First therapeutic experience with cis-platinum(II)diamindichloride (NSC 119875) in metastasizing ovarian and testicular carcinoma].

Ten patients with metastatic testicular or ovarian carcinoma were treated with cis-platinum II diaminedichloride. All had received prior chemotherapy with other agents. A therapeutic effect was seen in 7 cases, though it was of short duration in all instances. The drug proved to be very nephrotoxic and caused marked bone marrow depression. The future of this highly effective cytostatic agent, either with different dosage schedules or in combination with other drugs, is discussed. The possibility of new platinum derivatives with a better therapeutic index is also mentioned.

Adult↗
PubMed1975

[Initial results with a epipodophyllotoxin derivative VP 16-213 in the treatment of acute leukemia].

Ten acute leukemia patients were treated with the new cytostatic agent VP 16-213. Almost all these patients had received previous therapy. One complete and two partial remissions were achieved, while one patient showed brief clinical improvement. VP 16-213 appears to be effective not only in acute monocytic leukemia, as therapeutic effects could also be observed in other forms of acute leukemia. VP 16-213 should further be tested in therapy of refractory acute leukemia patients as a drug of second choice. The relatively mild toxic effect of this substance and its special mode of action would appear to make it highly suitable for incorporation into combination chemotherapy regimes and further clinical trials.

Acute Disease↗